


**Product Name** : XMU-MP-3  
**Cat. No.** : PC-73045  
**CAS No.** : 2031152-08-4  
**Molecular Formula** : C<sub>27</sub>H<sub>27</sub>F<sub>3</sub>N<sub>8</sub>O  
**Molecular Weight** : 536.563  
**Target** : BTK  
**Solubility** : 10 mM in DMSO



## Biological Activity

XMU-MP-3 is a potent, selective, noncovalent **BTK** inhibitor with IC<sub>50</sub> of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation.

XMU-MP-3 inhibited BTK-transformed Ba/F3 cell proliferation with an IC<sub>50</sub> of 11.4 nM, with negligible anti-proliferative effects on parental wild-type Ba/F3 cells (IC<sub>50</sub>>10 μM).

XMU-MP-3 inhibited both the autophosphorylation and trans-phosphorylation of BTK at residues Y223 and Y551, in a dose-dependent manner in BTK-transformed Ba/F3 cells at concentrations as low as 100 nM and completely suppressed at 1,000 nM.

XMU-MP-3 was considerably less potent (IC<sub>50</sub>, 2,815 nM) against proliferation of BTK(T474M)-transformed Ba/F3 cells.

XMU-MP-3 inhibits the growth of malignant B-cells, inhibited phosphorylation of PLCγ2 at Y1217 and Y759, substantially suppresses tumour growth in mouse xenograft models.

XMU-MP-3 maintained inhibitory potency with an IC<sub>50</sub> of 182.3 nM against BTK(C481S)-Ba/F3 cells and with an IC<sub>50</sub> of 17.0 nM in biochemical assays, suppressed ibrutinib-resistant BTKC481S mutation in vivo.

## References

Gui F, et al. *Br J Pharmacol*. 2019 Dec;176(23):4491-4509.

Wang H, et al. *Hematol Oncol*. 2021 Dec;39(5):605-615.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com